Indeed, future clinical investigations of fatty acid metabolism defects in SMA patients treated with SMN gene-based therapies will be essential to better understand the nature of the metabolic perturbations and the contribution of different CNS and peripheral tissues to the fatty acid metabolism defects. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.